Skeletal dysplasias

A baby born at term with a very narrow chest and short limbs develops grunting respiratory distress in the delivery room and is intubated with difficulty; the chest radiograph shows short horizontal ribs and a small thorax, and the question is whether this is a lethal dysplasia. Down the corridor, a two-year-old with rhizomelic short limbs, a large head, and trident hands attends clinic for growth and developmental surveillance, and her parents ask whether any treatment can increase her adult height. In both rooms the unifying task is to recognise a skeletal dysplasia, group it by its molecular pathway, and match the management to whether it is lethal or compatible with long life. ^{[1] [10]}

Overview & Definition

A skeletal dysplasia is an inherited disorder in which a gene that governs cartilage or bone development is altered, so that the skeleton grows abnormally in shape, length, or density from early fetal life onward. The skeleton forms by two routes — endochondral ossification, where a cartilage template is replaced by bone at the growth plate, and intramembranous ossification, where bone is laid down directly — and most dysplasias disturb endochondral ossification at the growth plate. The result is disproportionate short stature, meaning the limbs are shortened relative to the trunk or one segment of the limb is shortened relative to another, and the disproportion distinguishes a skeletal dysplasia from the proportionate short stature of endocrine, nutritional, or constitutional causes. ^{[2] [5]}

The 2019 revision of the international nosology lists four hundred and sixty-one distinct skeletal disorders in forty-two groups, defined by their causative gene and their clinical and radiographic phenotype. The number is daunting, but a small cluster of diagnoses accounts for most clinical encounters: achondroplasia is the commonest non-lethal dysplasia, osteogenesis imperfecta is the commonest dysplasia seen in general paediatric fracture practice, and thanatophoric dysplasia is the commonest lethal dysplasia recognised at birth. Mastering these three, together with the principle that the molecular pathway predicts the management, equips the candidate to reason through almost any skeletal dysplasia vignette. ^{[3] [4]}

The single most useful clinical concept is the lethal versus non-lethal dichotomy, because it sets the entire management trajectory. A lethal dysplasia — thanatophoric dysplasia, achondrogenesis, osteogenesis imperfecta type II, and the short-rib polydactyly syndromes — causes death from respiratory failure in the perinatal period because the small thorax cannot support lung inflation, and the management shifts to palliation, accurate molecular diagnosis for recurrence counselling, and prenatal diagnosis in future pregnancies. A non-lethal dysplasia such as achondroplasia or osteogenesis imperfecta types I, III, and IV is compatible with a normal lifespan and intellect, and the task becomes surveillance, therapy, and psychosocial support. Naming this dichotomy at the first consultation frames every later decision. ^{[2] [10]}

References13ShowHide

1. [1]Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis, 2019.PMID 30606190
2. [2]Krakow D, Rimoin DL. The skeletal dysplasias. Genet Med, 2010.PMID 20556869
3. [3]Mortier GR, Cohn DH, Cormier-Daire V, Hall C, Krakow D, Mundlos S, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A, 2019.PMID 31633310
4. [4]Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A, 2011.PMID 21438135
5. [5]Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet, 2007.PMID 17630040
6. [6]Baujat G, Legeai-Mallet L, Finidori G, Cormier-Daire V, Le Merrer M. Achondroplasia. Best Pract Res Clin Rheumatol, 2008.PMID 18328977
7. [7]Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet, 2020.PMID 32891212
8. [8]Forlino A, Marini JC. Osteogenesis imperfecta. Lancet, 2016.PMID 26542481
9. [9]van Dijk FS, Pals G, van Rijn RR, Nikkels PG, Cobben JM. Osteogenesis Imperfecta: A Review with Clinical Examples. Mol Syndromol, 2011.PMID 22570641
10. [10]Krakow D. Skeletal dysplasias. Clin Perinatol, 2015.PMID 26042906
11. [11]Krakow D, Lachman RS, Rimoin DL. Guidelines for the prenatal diagnosis of fetal skeletal dysplasias. Genet Med, 2009.PMID 19265753
12. [12]Kim HY, Ko JM. Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood. Ann Pediatr Endocrinol Metab, 2022.PMID 35793999
13. [13]Offiah AC, Hall CM. Radiological diagnosis of the constitutional disorders of bone. As easy as a, b, c? Pediatr Radiol, 2003.PMID 12612812